Establishment of transcriptional class distinction in melanocytes.

Slides:

Advertisements

Similar presentations

Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.

Advertisements

Key differences in protein expression and pathway activation between SCLCs and NSCLCs. A, for each cell line, protein lysates were collected and analyzed.

miR-133a positively regulated p53/p21 pathway.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Fig. 6. Pathway analysis of CMLD

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

Diverse abnormalities manifest in RNA

MITF upregulation leads to Hsp90i resistance

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Chromosome 8 cDNA microarray gene expression profile of the amplified regions of 8p11–12 in SUM-44, -52, and -225 cells versus MCF10A HME control cells.

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

AMPK induces VEGF-A production by upregulating ERK signaling.

Pharmacologically inhibiting BRAF/ERK and CDK4 restores APCFZR1 E3 ligase activity. Pharmacologically inhibiting BRAF/ERK and CDK4 restores APCFZR1 E3.

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

USP2a overexpression modifies the microRNA expression profile of prostate cells. USP2a overexpression modifies the microRNA expression profile of prostate.

Proposed model of how USP2a-driven microRNA deregulation enhances MYC protein expression through impairment of the MDM2–p53 pathway. p53 regulates miR-34b/c.

P38 activation mediates chronic insulin-induced IRS1 and IRS2 degradation and is involved in myocardial insulin resistance in vitro. p38 activation mediates.

USP2a regulates MYC expression through the MDM2–p53 axis.

TNFα is an important survival and growth signal for melanoma.

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Expression analysis of IGFBP-3 using human whole-genome microarray.

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

Induction of CDCP1 is regulated by Ras in NSCLC cells.

Protein expression profile in a dasatinib-resistant cell line.

AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2. AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2.

Dephosphorylation of pocket proteins in response to AG1024.

Oncogenic indel hotspots.

Expression of FGF2, IGF-1R, and IR in melanoma cells compared with normal melanocytes. Expression of FGF2, IGF-1R, and IR in melanoma cells compared with.

pRb turnover in melanoma cells and normal melanocytes.

Radiosensitization by combined Wee1 and PARP inhibition.

Lamellarin D induces cell death through a Fas-independent pathway.

Sensor siRNAs can be used in high-order combinations.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Effect of other nucleoside analogues on p38 MAPK phosphorylation levels. Effect of other nucleoside analogues on p38 MAPK phosphorylation levels. A, MM.1S.

Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.

ONC201 activates an ISR, decreases cyclin D1 expression, and causes an accumulation of cells in G1 in TNBC cells sensitive to the compounds' antiproliferative.

The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. A,

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

HCCs with overexpression of biliary/progenitor marker genes.

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

Potential model of HMQ1611 inhibiting breast cancer cell proliferation

HES1-dependent activation of SRC/STAT3 pathway is mediated by transcription-independent mechanism. HES1-dependent activation of SRC/STAT3 pathway is mediated.

EGFR signaling regulates transcription of PDGFRβ gene.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Knockdown of ERBB3, NRG1, or ERBB2 in H358-TwistER cells reduces basal PI3K–AKT signaling and ablates serum-independent proliferation before EMT. A and.

MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E. MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E.

Expression data from genes involved in regulation of transit through the cell cycle in response to treatment with E2 and OHT. A. Expression data from genes.

The effects of AZD1775 and olaparib on DNA damage response signaling.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Identification of RASA1- and NF1-mutated lung cancer cell lines in the CCLE dataset (accessed via the cBioPortal for Cancer Genomics at

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

CPGL is a growth suppressor in pancreatic cancer cell lines.

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

Characterization of Lkb1-WT and Lkb1-null cell lines.

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

NF1-associated and sporadic MPNST cell lines show a decrease in cell viability, soft agar colony formation, and xenograft tumor growth when Wnt/β-catenin.

An overview of the MAPK signaling pathway with points of therapeutic intervention indicated. An overview of the MAPK signaling pathway with points of therapeutic.

Integrated analysis of gene expression and copy number alterations.

Genomic and proteomic profiling of ovarian cancer cell lines.

AXL is not necessary for maintenance of intrinsic resistance.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Presentation transcript:

Establishment of transcriptional class distinction in melanocytes. Establishment of transcriptional class distinction in melanocytes. A, effects of aberrant MAPK pathway activation on melanocyte whole-genome expression profiles. B, effects of aberrant MAPK pathway activation on markers of the MITF-high and NF-κB–high classes; E, VTX11E (ERKi); P, PLX4720 (RAFi); A, AZD6244 (MEKi), all overnight at 2 μmol/L. C, effects of chronic BRAFV600E expression on markers of the MITF-high and NF-κB–high classes. Experiments were performed in TICVA medium (+) or Ham's F10 (−) as indicated. D, effect of MITF overexpression on MAPK pathway–induced expression changes. n.s., nonspecific band. E, relationship between MITF expression levels and MITF amplification in melanoma cell lines. David J. Konieczkowski et al. Cancer Discovery 2014;4:816-827 ©2014 by American Association for Cancer Research